专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070135404A1 Respiratory Syncytial Virus Replication Inhibitors 失效
标题翻译：呼吸道合胞病毒复制抑制剂
公开(公告)号：US20070135404A1
公开(公告)日：2007-06-14
申请号：US11625648
申请日：2007-01-22
申请人： Frans Janssens , Kathleen Meersman , Francois Sommen , Koenraad Marcel Andries
发明人： Frans Janssens , Kathleen Meersman , Francois Sommen , Koenraad Marcel Andries
IPC分类号： A61K31/551 , A61K31/55 , A61K31/4745 , A61K31/4184 , C07D471/02 , C07D403/02
CPC分类号： C07D401/12 , C07D401/14 , C07D471/04 , Y02P20/55
摘要： This invention concerns compounds of formula (I) prodrugs, addition salts, or stereochemically isomeric forms thereof for use as, inter alia, respiratory syncytial virus replication inhibitors; their preparation, compositions containing them and methods of their use in treating respiratory syncytial viral infections.
摘要翻译：本发明涉及用作呼吸道合胞病毒复制抑制剂等的式（I）化合物前药，加成盐或立体化学异构体形式; 它们的制备方法，含有它们的组合物和它们用于治疗呼吸道合胞病毒感染的方法。

2. 发明申请

US20050234047A1 Respiratory syncytial virus replication inhibitors 失效
标题翻译：呼吸道合胞病毒复制抑制剂
公开(公告)号：US20050234047A1
公开(公告)日：2005-10-20
申请号：US11144103
申请日：2005-06-03
申请人： Frans Janssens , Kathleen Petrus Meersman , Francois Sommen , Jerome Georges Guillemont , Jean Armand Lacrampe , Koenraad Marcel Andries
发明人： Frans Janssens , Kathleen Petrus Meersman , Francois Sommen , Jerome Georges Guillemont , Jean Armand Lacrampe , Koenraad Marcel Andries
IPC分类号： A61K31/00 , A61K31/4184 , A61K31/4188 , A61K31/443 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4745 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/55 , A61K31/551 , A61P31/12 , A61P31/14 , C07D401/06 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04
CPC分类号： A61K31/4184 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4745 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/551 , C07D235/24 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04
摘要： This invention concerns the use of compounds of formula (I) wherein -a1=a2-a3=a4- is a radical of formula —CH═CH—CH═CH—, —N═CH—CH═CH—, —CH═N—CH═CH—, —CH═CH—N═CH—, —CH═CH—CH═N— wherein each hydrogen atom may optionally be substituted; Q is a radical of formulas (b-1), (b-2), (b-3), (b-4), (b-5), (b-6), (b-7), (b-8), G is a direct bond or C1-10alkanediyl; R1 is an optionally substituted monocyclic heterocycle; for the manufacture of a medicament for the treatment of viral infections, in particular RSV infections. Certain compounds of formula (I) are new.
摘要翻译：本发明涉及式（I）化合物的用途，其中-a-1-a- 是式-CH-CH-CH-CH-，-N-CH-CH-CH-，-CH-N-CH-CH-，-CH-CH-N-CH-， - CH-CH-N-，其中每个氢原子可以任选被取代; Q是式（b-1），（b-2），（b-3），（b-4），（b-5），（b-6），（b-7） -8），G为直链或C 1-10烷二基; R 1是任选取代的单环杂环; 用于制备用于治疗病毒感染，特别是RSV感染的药物。某些式（I）化合物是新的。

3. 发明申请

US20060142279A1 Treatment of latent tuberculosis 审中-公开
标题翻译：治疗潜伏性结核病
公开(公告)号：US20060142279A1
公开(公告)日：2006-06-29
申请号：US11296992
申请日：2005-12-08
申请人： Koenraad Marcel Andries , Anil Koul
发明人： Koenraad Marcel Andries , Anil Koul
IPC分类号： A61K31/541 , A61K31/5377 , A61K31/496 , A61K31/4709
CPC分类号： A61K31/47 , A61K31/4704
摘要： Use of a compound of formula (Ia) or (Ib) for the manufacture of a medicament for the treatment of latent tuberculosis, wherein the compound of formula (Ia) or (Ib) is a pharmaceutically acceptable salt, a quaternary amine, a N-oxide, a tautomeric form or a stereochemically isomeric form thereof wherein R1 is hydrogen, halo, haloalkyl, cyano, hydroxy, Ar, Het, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; p is 1, 2, 3 or 4; R2 is hydrogen, hydroxy, mercapto, alkyloxy, alkyloxyalkyloxy, alkylthio, mono or di(alkyl)amino or a radical of formula ;R3 is alkyl, Ar, Ar-alkyl, Het or Het-alkyl; q is zero, 1, 2, 3 or 4; R4 and R5 each independently are hydrogen, alkyl or benzyl; or R4 and R5 may be taken together including the N to which they are attached; R6 is hydrogen, halo, haloalkyl, hydroxy, Ar, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; or two vicinal R6 radicals may be taken together to form a bivalent radical —CH═CH—CH═CH—; r is 1, 2, 3, 4 or 5; R7 is hydrogen, alkyl, Ar or Het; R8 is hydrogen or alkyl; R9 is oxo; or R8 and R9 together form the radical ═N—CH═CH—.
摘要翻译：式（Ia）或（Ib）化合物在制备用于治疗潜伏性结核病的药物中的用途，其中式（Ia）或（Ib）化合物是药学上可接受的盐，季胺，N 氧化物，互变异构形式或其立体化学异构体形式，其中R 1是氢，卤素，卤代烷基，氰基，羟基，Ar，Het，烷基，烷氧基，烷硫基，烷氧基烷基，烷硫基烷基，或二（Ar）烷基; p为1,2,3或4; R 2是氢，羟基，巯基，烷氧基，烷氧基烷氧基，烷硫基，一或二（烷基）氨基或式的基团; R 3是烷基，Ar，Ar - 烷基，Het或Het-烷基; q为零，1,2,3或4; R 4和R 5各自独立地是氢，烷基或苄基; 或R 4和R 5可以一起包括它们所连接的N; R 6是氢，卤素，卤代烷基，羟基，Ar，烷基，烷氧基，烷硫基，烷氧基烷基，烷硫基烷基，芳烷基或二（Ar）或两个邻位R 6个基团可以一起形成二价基团-CH-CH-CH-CH-; r为1,2,3,4或5; R 7是氢，烷基，Ar或Het; R 8是氢或烷基; R 9是氧代; 或R 8和R 9一起形成基团-N-CH-CH-。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式